Trial Profile
Efficacy of LCZ696 on amyloid-beta concentrations in cerebrospinal fluid in healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2016
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Essential hypertension; Heart failure; Kidney disorders
- Focus Pharmacodynamics
- 12 Jan 2016 New trial record
- 12 Dec 2015 The primary endpoint (Changes in area under the effect curve concentration from baseline) has been not met according to results published in the British Journal of Clinical Pharmacology
- 12 Dec 2015 Results published in the British Journal of Clinical Pharmacology